Session 6: Expanding the Toolbox: Integrating Pharmacotherapy and Bariatric Surgery

1. Obesity is a metabolic disease that impacts dozens of tissues and organ systems.

a) True
b) False

2. 2023 American Academy of Pediatrics Clinical Practice Guideline for Child & Adolescent Obesity recommends the consideration of pharmacotherapy as an adjunctive approach to address childhood obesity in children 12 years old and older.

a) True
b) False

3. A number of medication options exist to manage childhood obesity; the decision to initiate, continue, modify, or terminate treatment should be based on patient-specific factors and shared decision-making between the patient and provider.

a) True
b) False

4. GLP-1 based medications have the following mechanisms of action:

a) Slows gastric emptying
b) Triggers insulin release
c) Prevents glucose from going into the bloodstream
d) Impacts brain processing to enhance satiety
e) All of the above

5. Phentermine was approved for pediatric weight management in the short term (up to 12 weeks), as an adjunct to diet and exercise for children 17 years old or older.

a) True
b) False

6. The following medication(s) have been approved for pediatric obesity management in children 12 years old or older:

a) Orlistat
b) Liraglutide
c) Phentermine/topiramate
d) Semaglutide
e) All of the above

7. Glucagon-like peptide receptor agonists do not increase the risk of suicidal ideation and attempt in adolescents.

a) True
b) False

8. The following classes of medications are FDA-Approved for pediatric obesity management:

a) Lipase inhibitors
b) Central nervous system stimulants
c) Melanocortin receptor agonist
d) Glucagon-like peptide receptor agonists
e) All of the above

9. Lifestyle treatment in teens has shown a reduction in symptoms of depression and eating disorders.

a) True
b) False